We read with interest the recent article by Haifer et al (Gut, 2022, 2022–3 27 742), which reported that donor gut microbiome stability and species evenness were associated with higher donor species engraftment in patients with UC following faecal microbiota transplantation (FMT). This has brought us one step closer towards the selection of optimal FMT donors. However, the high prevalence of extended‐spectrum beta‐lactamase organisms and the COVID‐19 pandemic have restricted the recruitment of FMT donors.1 An alternative means to increase the stability and species evenness is to pool the stool samples from multiple eligible FMT donors, which has been shown to be associated with higher clinical efficacy in UC.2 In obesity-related metabolic disorders, outcomes following FMT have been variable.3–8 Although the underlying mechanisms are unclear, the efficacy of FMT is likely to be affected by both donor and recipient microbiota composition.4 9–12 Therefore, we performed a pilot study of single-donor faecal microbiota transplantation (sFMT) and compared the findings with our previous mixed-donor faecal microbiota transplantation (mFMT) study,8 with the aim to determine microbiome factors associated with response to FMT in obese subjects (NCT03789461). Nine obese subjects received faecal infusions from a single lean donor, whereas 38 obese subjects received faecal infusions from two to five lean donors (table 1 and online supplemental table S1). Overall, FMT was safe and well tolerated (online supplemental table S2). After FMT, 13.2% of mFMT recipients (responders) and none of the sFMT recipients achieved ≥10% weight loss (mean±SD, mixed-donor 3.1%±4.8%, single-donor 4.8%±1.7%; online supplemental figure S1). mFMT recipients showed significant reductions of low-density lipoprotein and total cholesterol at weeks 24 …

中文翻译：

---

混合供体粪便微生物群移植与肥胖产生丁酸盐的细菌增加有关

我们感兴趣地阅读了 Haifer 等人最近发表的文章 (Gut, 2022, 2022–3 27 742)，该文章报道，供体肠道微生物组稳定性和物种均匀性与粪便微生物群移植 (FMT) 后 UC 患者较高的供体物种植入相关）。这使我们在选择最佳 FMT 捐献者方面又近了一步。然而，超广谱 β-内酰胺酶生物体的高流行和 COVID-19 大流行限制了 FMT 供体的招募。1 提高稳定性和物种均匀性的另一种方法是汇集来自多个合格 FMT 供体的粪便样本，这已被证明与 UC 的较高临床疗效相关。2 在肥胖相关代谢性疾病中，FMT 后的结果各不相同。3-8 尽管根本机制尚不清楚，但 FMT 的疗效可能会受到两者的影响供体和受体的微生物群组成。4 9–12 因此，我们进行了一项单供体粪便微生物群移植 (sFMT) 的试点研究，并将研究结果与我们之前的混合供体粪便微生物群移植 (mFMT) 研究进行比较，8 旨在确定与肥胖受试者 FMT 反应相关的微生物组因素 (NCT03789461)。 9 名肥胖受试者接受来自单个瘦捐献者的粪便输注，而 38 名肥胖受试者接受来自 2 至 5 名瘦捐献者的粪便输注（表 1 和在线补充表 S1）。总体而言，FMT 是安全且耐受性良好的（在线补充表 S2）。 FMT 后，13.2% 的 mFMT 接受者（有效者）和 sFMT 接受者均未达到 ≥10% 的体重减轻（平均值±SD，混合捐赠者 3.1%±4.8%，单一捐赠者 4.8%±1.7%；在线补充图 S1 ）。 mFMT 接受者在第 24 周时低密度脂蛋白和总胆固醇显着降低……